About
Trially, founded in 2023 in Kansas City, Missouri, USA, uses AI to match, reach, and recruit patients for clinical trials to reduce enrollment delays.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2025-09Seed$5M
Investors · Atria, Flyover Capital, Blu Ventures, Alpaca VC, Looking Glass Capital, Redbud, The Council, GaingelsSource · SVTR Weekly #123
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Trially
AI to match, reach and recruit patients for clinical trials
Seed · $5M · 2025-09
$5M
United States
BusinessLatest roundTotal raisedDate- Valinor
Models trained on multi-omics/longitudinal clinical data to predict clinical trial efficacy and stratify patients
Seed · $13M · 2025-12
$13M - BioPhy
AI-generated quantitative metrics on the likelihood of success of drugs and clinical trials
Seed · $5M · 2023-11
$5M - RyboDyn
AI-driven sequencing and discovery platform decoding the "dark proteome" to find cancer-specific cryptic targets in patient tumors that conventional methods miss, for first-in-class cancer immunotherapies
Seed · $14M · 2026-03
$14M
China
BusinessLatest roundTotal raisedDate- Purui Intelligence
AI-driven platform for end-to-end clinical trial automation and results delivery.
Series A · $14M · 2026-06
$14M - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M - Deep Pharma
AI-driven drug discovery and clinical development platform
Series D+ · $200M · 2026-03
$200M
Europe
BusinessLatest roundTotal raisedDate- CardiaTec
Uses AI and large-scale multi-omics data to discover new therapies for cardiovascular disease
Seed · $7M · 2024-09
$7M - Amply
AI-accelerated development of gene-silencing therapies for aggressive cancers and inhaled antimicrobials for drug-resistant infections
Seed · $4M · 2025-05
$4M - OutSee
AI analysis of individual genomes to predict disease biology and help drug developers find new targets
Seed · $2M · 2025-06
$2M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
39 Life Sciences deals in the last 24 months · 18 at a nearby stage · 35 in United States
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 26 at a nearby stage · 31 in United States
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 11 at a nearby stage · 22 in United States
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 7 at a nearby stage · 20 in United States
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 3 at a nearby stage · 15 in United States
Request intro →Lightspeed
16 Life Sciences deals in the last 24 months · 5 at a nearby stage · 14 in United States
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.